Hamideh Moayedpardazi
Ophthalmology · Montebello, CANPI 1386933240
Payments from drug & device makers
Across 153 payments — averaging $46.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- AbbVie$2K
- Alcon$1K
- Carl Zeiss Meditec USA, Inc.$261
- Nova Eye, Inc.$259
- Bausch & Lomb, A Division Of Bausch Health US, LLC$125
- plus $345 from 8 others
What the payments were for
- Speaking & faculty fees$5007%
- Food & beverage$6,66593%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 30 | $3,039 |
| AbbVie(2 entities) | 69 | $1,960 |
| Alcon | 30 | $1,195 |
| Carl Zeiss Meditec USA, Inc. | 3 | $261 |
| Nova Eye, Inc. | 2 | $259 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $125 |
| Novartis | 7 | $122 |
| Sun Pharmaceutical Industries Inc. | 3 | $83 |
| Amgen | 2 | $38 |
| Shire North American Group Inc | 2 | $32 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Thea Pharma Inc. | 1 | $18 |
| NEW World Medical,inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$719
- iStent Trabecular Micro-Bypass Stent System$668
- iStent inject Trabecular Micro-Bypass Stent System$668
- XEN GLAUCOMA TREATMENT SYSTEM$596
- IACCESS$311
- iStent Trabecular Micro-Bypass System Model iS3$292
- KXL System$283
- AcrySof$279
- iStent infinite Trabecular Micro-Bypass System Model iS3$206
- iStent$142
- Photrexa$141
- Clareon$126
- LOTEMAX SM$125
- Luxor$112
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$103
- QUATERA 700$101
How this compares
$7,183 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 3,742 | $1,797,108 |
| Alphagan PBrimonidine Tartrate | 824 | $314,889 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 853 | $268,643 |
| Brimonidine Tartrate | 1,253 | $234,708 |
| RestasisCyclosporine | 190 | $139,908 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 737 | $121,062 |
| Cyclosporine | 343 | $101,689 |
| CombiganBrimonidine Tartrate/Timolol | 236 | $90,319 |
| RhopressaNetarsudil Mesylate | 141 | $79,567 |
| Brinzolamide | 425 | $70,913 |
| RocklatanNetarsudil Mesylat/Latanoprost | 98 | $57,164 |
| XiidraLifitegrast | 67 | $56,661 |
| Restasis MultidoseCyclosporine | 81 | $52,949 |
| Prednisolone Acetate | 726 | $24,170 |
| Latanoprost | 1,977 | $22,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan, Restasis Multidose | $1,960 | $2,395,1735,073 claims |
| AlconSimbrinza | $1,195 | $268,643853 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $25 | $136,732239 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $18 | $76,97999 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $125 | $8,85974 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Montebello
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.